Prediction Case File
YouTubeEvaluation Complete

Is Eli Lilly Stock an Undervalued Stock to Buy? | LLY Stock Discounted Cash Flow Valuation

1 extracted signal · 0 resolved · 0 still active

Parkev Tatevosian, CFA profile imageParkev Tatevosian, CFAIndependent analyst profile
Source published
25 May 2026, 11:45 UTC
Recorded by Tahlil Plus
25 May 2026, 11:47 UTC
Video preview for Is Eli Lilly Stock an Undervalued Stock to Buy? | LLY Stock Discounted Cash Flow Valuation
Source overview

AI-generated source summary

Eli Lilly and Company (LLY) is projected to generate $90 billion in free cash flow over the next decade, driven by its weight loss treatments and innovations. The company's weighted average cost of capital (WACC) is 6.79%, and its beta is 0.585, indicating lower volatility compared to the market. The market risk premium is 6%. Using a discounted cash flow model, the present value of operations is estimated at $1,304,790,000,000 and the terminal value at $1,806,878,400,000. The value of equity is calculated at $1,277,187,609,320, resulting in an intrinsic value per share of $1,356.16. This intrinsic value is significantly higher than the current market price of $809.64, suggesting the stock is undervalued. The low beta and WACC suggest a relatively stable and low-risk investment, with expected future cash flows supporting a bullish outlook.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
1
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Source processing completed

    Source analysis and structured extraction completed.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  7. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

Parkev Tatevosian, CFA

Platform-wide history, separate from this source evaluation.

Reliability
41.8
Tracked signals
1293
Historical success
25.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail